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Abstract 
Lactose, a disaccharide is a ubiquitous excipient in many pharmaceutical formulations 
which exists in two anomeric forms; either as α- or β-lactose. The anomers have different 
properties which can affect their application. Nevertheless, batches of lactose products are 
widely produced by many manufacturers, and is available in many grades. However, the 
anomeric content of these batches has not been accurately characterized and reported 
previously. Therefore, the aim of this study was to analyse a set of 19 commercially 
available samples of lactose using a novel H1-NMR technique to establish a library showing 
the anomeric content of a large range of lactose products. The lactose samples were also 
analysed by DSC. The anomeric content of the α-lactose monohydrate samples were found 
to vary by more than 10 %, which might influence bioavailability from final formulations. The 
data showed that there is a need to determine and monitor the anomeric content of lactose 
and this should be a priority to both manufacturers and formulators of medicines.  
Keywords: 
Lactose (grades); anomer; α-lactose, β-lactose, NMR; DSC; excipient; 
epimerisation/mutarotation; survey 
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1 Introduction 
1.1 Lactose 
Lactose is a disaccharide formed through a β-1,4-glycosidic bond between α/β-D-
glucose and β-D-galactose (Berg et al., 2002; Jawad et al., 2012). It has many uses in 
pharmaceutical formulations, with its advantageous properties including: low cost, inert 
nature, safety and low hygroscopicity (Jivraj et al., 2000). It is used extensively in tablet 
formulations as a bulking agent, being present in an estimated 70% of commercially 
available tablets (Illanes, 2016). Lactose is often incorporated in dry powder inhalers (DPIs) 
where it can fulfill the triple function of bulking agent, flow aid and carrier particle (Chow et 
al., 2007; Kinnunen et al., 2014). Approximately 6 million tons of lactose are produced yearly 
to supply the worldwide market (Geiger et al., 2016). 
Lactose has two anomeric forms, termed α and β. These forms exist as a consequence 
of an orientational change of the hydrogen and hydroxyl groups around the chiral centre on 
the C1 carbon (Jawad et al., 2014). They have different non-superimposable chemical 
structures that could be considered as different chemical species.  
1.2 Lactose anomers 
Lactose is typically isolated from whey, which is produced as a byproduct from cheese-
making (Keri Marshall, 2004). Several crystallization steps are used to purify the end 
product. When crystallization is carried out at high temperatures (93.5°C or above) the 
sample contains a high proportion of anhydrous β-lactose crystals; whereas α-lactose 
monohydrate crystals are predominantly obtained if crystallization is conducted closer to 
room temperature (Wade and Weller, 1994). Thus, the distinct molecular structures 
associated with these anomers of lactose leads to the generation of a range of solid forms 
for lactose, which possess different physiochemical properties (Pharma, 2017). For 
example, anhydrous crystalline β-lactose has a solubility in water that is seven times that of 
crystalline α-lactose monohydrate in water (Illanes, 2016).  
As a consequence, the form of lactose might be crucial to the efficiency and bioavailability 
of the active pharmaceutical ingredient in both medicines containing lactose (Tsujikawa et 
al., 2016) and even tablet formulations of drugs of abuse (Wawer, 2008). In tablets, the role 
of lactose is not only to serve as a bulking agent (to ensure uniformity of dose) but also to 
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improve the physical strength of tablets, and it is used for the same purposes by illicit tablet 
manufacturers (Chalmers et al., 2012).  
Commercially available lactose powders that are used in tablets may show a range of 
anomeric compositions spanning those that are composed predominantly of α-lactose 
through to those comprising predominantly β-lactose (Pharma, 2017). The solid forms that 
these anomers may adopt adds another layer of complexity, for example the different 
anomers may be isolated as amorphous solids or under specific conditions they may 
combine to form anomeric co-crystals (Simpson et al., 1982). The solid forms in which 
lactose can exist are summarized below in Figure 1. 
Figure 1 The solid forms of lactose available for manufacture (Adapted from Jawad et al., 2015 with 
permission) 
 
Crystalline α-lactose monohydrate is one of the most stable forms of lactose but it can be 
dehydrated into both stable and an unstable anhydrous forms of α-lactose by the application 
of heat (Alderborn, 2002). In contrast, β-lactose only forms an anhydrous product and this 
form of lactose can be more favourable than other lactose forms because of its compression 
properties (Jawad et al., 2015). However, ‘anhydrous β-lactose’ typically contains 15% w/w 
of anhydrous α-lactose as an impurity. In fact, it is probable that most lactose products will 
contain an impurity of the anomer other than that stated within the product descriptor.  
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An important mechanism of lactose is called mutarotation where α- and β-lactose anomeric 
forms interchange in a solution until a temperature-sensitive equilibrium is established. This 
is considered when processing lactose as some preparation methods require lactose to be 
in a solution temporarily such as in spray-drying. A study also found that mutarotation may 
occur in solid state samples that are exposed to high humidity and temperature (Altamimi et 
al., 2017).  
The mutarotation of lactose follows the same mechanics as the mutarotation of related 
sugars such as glucose (Silva et al., 2006) and has been described in detail elsewhere 
(Jawad et al., 2012). This occurs through the formation of a free aldehyde form from the 
glucose molecule in the lactose structure (  
 
Figure 2). The aldehyde forms as a result of a protonation of the oxygen (O5 in   
 
Figure 2), which precedes the breakage of the hydrogen bond of the O1 (Altamimi et al., 
2017; Jawad et al., 2012; Lefort et al., 2006). In solution, the two forms interconvert until 
they reach an equilibrium depending on the pH and temperature of the solution (  
 
Figure 2).  
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Figure 2 The forms of lactose that exist during mutarotation 
 
 
In lactose containing products, the anomeric content is very often scarcely reported. Even 
the European Pharmacopoeia does not consider anomeric content reporting as an obligatory 
requirement to include in the specifications of lactose products (Rowe et al., 2006). The 
crystallinity or amorphous content of lactose batches has been reported extensively in 
previous studies (Altamimi et al., 2017; GombÁs et al., 2002; Islam and Langrish, 2010; 
Jawad et al., 2014; Jawad et al., 2012; Jawad et al., 2015). However, the anomeric 
composition of the wide range of commercially available lactose powders has not been 
investigated and there appears to be a clear need to develop rapid methods for this purpose. 
 
1.3 Analytical methods used to determine the solid anomeric form of lactose 
powders 
A variety of analytical techniques have been used to determine the presence and the 
form of lactose for the quality control of pharmaceuticals and have the potential to be 
employed in forensic science. Although nearly all of these techniques are sensitive to the 
anomeric composition of lactose, for reasons of signal complexity, run time, sample 
presentation and detection limits, none have been employed to characterize the variation in 
anomeric content of the broad range of lactose powders that are available to the formulation 
scientist. Spectroscopic methods for analyzing lactose powders include near infrared 
reflectance spectroscopy (NIR), terahertz (THZ) spectroscopy and Raman spectroscopy 
(Baer et al., 2007; Chalmers et al., 2012). For example, Raman spectroscopy has been 
employed to distinguish successfully the difference between genuine and counterfeit tablets 
(Trefi et al., 2008). Powder X-ray diffraction (PXRD) can be used to identify the anomeric 
crystal type (Farber et al., 2003), however if the sample is not crystalline, i.e. amorphous, 
PXRD is unable to differentiate between the anomeric forms of lactose. Dynamic vapour 
sorption (DVS) is another technique that can be used to determine the amorphous content of 
a sample containing a mixture of crystalline and amorphous material due to changes in the 
sorption profile that is attributed to the amorphous content (Mackin et al., 2002). However, it 
should be noted that when using DVS samples with low levels of amorphous content, large 
errors may occur due to the surface adsorbed moisture.  
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In terms of pharmaceutical analysis, although these diffraction and spectroscopy-based 
techniques are non-destructive, they do require a powdered sample that is representative of 
the whole material that is being studied. Other methods have also been employed to 
characterize the physical properties of solid phase lactose (Table 1). 
There are several issues regarding the manufacturer’s specifications of anomeric content of 
lactose samples that are available commercially. First, even if specifications are provided, 
the amount of α- and β-lactose in the powder is not detailed precisely. Should the anomeric 
purity be mentioned, it is given as a range, for example >98% w/w, rather than a 
determination of the exact anomeric content (ANON, 2017). Second, the anomeric content is 
sensitive to the environment and can change if the products are not stored under 
appropriate conditions. For example, when stored at high humidity and temperature (i.e. 
>90% RH and 40°C) the anomeric content of crystalline β-lactose powder changes as a 
function of time; with an increasing percentage of α-lactose anomer forming in the powder 
(Altamimi et al., 2017). Due to the differences in properties between α- and β-lactose 
anomers, it is likely that storage conditions of lactose containing products should be 
controlled to prevent possible alteration in biopharmaceutical profiles of formulated 
medicines.
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DSC has been widely used to analyze lactose in terms of assessing sample crystallinity 
(Table 1) and in some cases to determine crystalline contaminants in anhydrous samples 
(Brittain and Blaine, 2018; GombÁs et al., 2002). Lactose in whey powder has been 
analysed using DSC, a much faster method of analysis (anomeric content determined within 
2 h), in comparison to the 6 h required for a polarimeter-based method (Ross, 1978). The 
DSC values for anomeric content have been reported to be within 5% of those obtained 
using polarimetry. This scrutiny in determination of the anomeric content of lactose has not 
been applied routinely to pharmaceutical products despite the inherent requirement for the 
highest available standards to be employed for medicines and commercial applications. The 
main disadvantage of DSC is that it requires crystalline samples, as it measures the enthalpy 
of fusion associated with the resolvable melting transitions for the anomeric forms of lactose 
respectively. However, when non-crystalline or amorphous lactose is heated the powder 
passes through a glass transition and then a subsequent re-crystallization. DSC is unable to 
differentiate between the glass transitions and re-crystallization peaks for the different 
anomeric forms of lactose. Thus, if amorphous material is a significant fraction of a lactose 
powder, DSC is unlikely to determine an accurate anomeric content. Even with the 
advantages of DSC methodology, the quantitative limitations are a possible reason as to 
why a more sophisticated technique might be advocated for characterizing lactose within 
medicines. NMR has been shown to be a candidate method for this purpose (Altamimi et al., 
2017). 
A gas chromatography method has been outlined in the British Pharmacopoeia and is 
currently employed by manufacturers that attempt to determine the anomeric content of their 
products (ANON, 2017). The method requires the preparation of a silylation reagent to 
derivatize lactose samples. Next a resolution mixture must be passed through the column 
before the lactose samples are introduced, so as to ensure that the resolution between the 
peaks is adequate (>3.0). For each sample, 10 mg of lactose needs to be dissolved in 4 mL 
of the silylation regent before the mixture is sonicated at room temperature for 20 min. 
Samples of this solution (400 µL) are then transferred to new vials and 1 mL of pyridine is 
introduced prior to assay (ANON, 2012). In comparison, the NMR analysis method was 
successful in determining the anomeric content measured without requiring derivitization, 
resolution mixtures or waiting times as required in the GC method (Jawad et al., 2012). 
C13 cross-polarization magic angle spinning NMR analysis of solid state lactose has also 
been used to differentiate between crystalline α-lactose monohydrate and stable anhydrous 
lactose (Lefort et al., 2006). The monohydrate form exhibits a single peak whereas the 
anhydrous form exhibits two peaks at 80-90 ppm corresponding to a carbon atom. 
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Additionally, the β-anomer of lactose exhibits a downfield shift of the C13 anomeric carbon 
peak when compared to the α-anomer. C13 NMR is a method that has to be conducted over 
a relatively longer time period than an H1 NMR (~6 min) method and the former technique is 
less sensitive due to the lower relative abundance of C13 (1.1%) compared to H1 (99%). On 
this basis, H1 NMR has been used successfully to determine the anomeric content of lactose 
due to the occurrence of two separate doublets corresponding to the α- and β-anomers of 
lactose in the spectrum between 6-7 ppm. The ratio of the two anomeric forms of lactose in 
the sample can be calculated by using the integrated areas of the peaks (Altamimi et al., 
2017; Jawad et al., 2014; Jawad et al., 2012). Some advantages of the NMR method include 
ease of preparation, non-ambiguous results and applicability to both amorphous and 
crystalline starting material.  
Therefore, it is clear that H1-NMR, a fast technique, can provide a clear interpretation of 
results with appropriate precision, rendering it a suitable method to analyse commercial 
lactose samples for anomer composition. 
The aim of the study reported here was to evaluate and further optimize a H1 NMR method 
for the determination of the variability in the anomeric content of commercially available 
lactose powders. DSC was used to initially characterize the lactose samples to investigate 
the potential shortcomings of analytical strategies that are based solely on measuring 
physical properties rather than true anomeric composition. 
2 Materials and Methods 
2.1 Materials 
The lactose samples were stored in the laboratory under ambient temperatures. The 
information regarding their specifications is noted below. For particle size please refer to 
supplementary material. The pertinent information for the present study given by the 
suppliers has been summarized in 
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Table 2. 
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Table 2 Summary of supplier information of commercially available lactose powders 
Sample name Supplier/Manufacturer & 
method of production. 
Information from product 
sheets, specification and 
materials data safety sheet 
(particle sizing given in 
appendix A). 
α−Lactose 
Monohydrate 
Sigma Aldrich: Method of 
production not given by supplier. 
> 99% total lactose, < 4 % w/w 
beta lactose. Chemical structure 
given as the monohydrate. 
Chemical reagent. 
Foremost 312 
Foremost Farms / Kerry: Milled 
lactose. 
Lactose monohydrate; Lactose 
99% w/w; % Water 4.5 to 5.5; 
Used for wet granulation and 
capsule filling. Highly crystalline. 
Tablettose 80 
Meggle: Spray-agglomeration – 
water sprayed onto fluidized fine 
milled lactose particles. 
Agglomerated alpha lactose 
monohydrate. Used for direct 
compression formulations and 
capsules. 
Prismalac 40 
Meggle: Coarse sieved alpha 
lactose monohydrate grades. 
Mono-crystals of alpha-lactose 
monohydrate. Used for capsule 
filing. 
Tablettose 70 
Meggle: Spray-agglomeration – 
water sprayed onto fluidized fine 
milled lactose particles. 
Agglomerated alpha lactose 
monohydrate, low fines content. 
Used for direct compression 
formulations, capsules and orally 
disintegrating tablets. 
Tablettose 100 
Meggle: Spray-agglomeration – 
water sprayed onto fluidized fine 
milled lactose particles. 
Agglomerated alpha lactose 
monohydrate, higher fines content. 
Used for direct compression 
formulations, capsules and orally 
disintegrating tablets. 
Ludipress 
BASF A granulated mixture of 
lactose monohydrate 93% w/w, 
Povidone K30 and Cropovidone. 
Lactose monohydrate is 
determined using a polarimetric 
assay. Used for direct 
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compression tableting. 
Granulac 140 
Meggle: Milled alpha lactose 
monohydrate crystals. 
! Alpha lactose 
monohydrate. Narrow particle size 
distribution; cohesive particles. 
Used as a diluent in dry and wet 
granulation processing. 
 
Granulac 230 
Meggle: Milled alpha lactose 
monohydrate crystals. 
! Alpha lactose 
monohydrate. Narrow particle size 
distribution, cohesive particles. 
Used as a diluent in dry and wet 
granulation processing. 
 
Sorbolac 400 
Meggle: Milled alpha lactose 
monohydrate crystals. 
! Alpha lactose 
monohydrate. Narrow particle size 
distribution, cohesive particles. 
Used as a diluent in dry and wet 
granulation processing. 
 
Starlac 
Meggle: Co processed - 85 %w/w 
alpha-lactose-monohydrate and 15 
%w/w white maize starch. 
! Used for direct 
compression formulations, 
capsules and orally disintegrating 
tablets. Spherical agglomerated 
particles with good flow properties. 
 
Granulac 70 
Meggle: Milled alpha lactose 
monohydrate crystals. 
Narrow particle size distribution, 
cohesive particles. Used as a 
diluent in dry and wet granulation 
processing. 
Flowlac 90 
Meggle: Spray-dried suspension of 
fine milled alpha-lactose 
monohydrate crystals in a solution 
of lactose. 
 
Spherical agglomerate shape, 
consisting of small alpha-lactose 
monohydrate crystals bound by 
amorphous lactose. Used for 
direct compression tablet 
formulations. 
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!  
Combilac 
Meggle: - Co processed 70 %w/w 
alpha-lactose monohydrate, 20 
%w/w microcrystalline cellulose 
(MCC) and 10 %w/w white, native 
corn starch. 
 
Used for direct compression 
formulations, dry granulation and 
orally disintegrating tablets. 
Spherical agglomerated particles 
with good flow properties. 
Flowlac 100 
Meggle: Spray-dried suspension of 
fine milled alpha-lactose 
monohydrate crystals in a solution 
of lactose. 
Spherical agglomerate shape, 
consisting of small alpha-lactose 
monohydrate crystals bound by 
amorphous lactose. Used for 
direct compression tablet 
formulations. 
 
Cellactose 
Meggle: Co processed - 75 %w/w 
alpha-lactose-monohydrate and 25 
%w/w powdered cellulose. 
Used for direct compression 
formulations tablets. Spherical 
agglomerated particles. 
Foremost 316 
Foremost Farms / Kerry: Lactose 
monohydrate modified spray-dried. 
 
A spray-dried mixture of crystalline 
and amorphous lactose Spherical 
particles; Lactose 99% w/w; % 
Water 4.5 to 5.5 Used for direct 
compression tablets and in 
capsule filling. 
MCC 25 
Foremost Farms / Kerry: 
Disintequick™ MCC 25 is a co-
processed Lactose/MCC at a ratio 
of 75:25 %w/w Alpha lactose 
Monohydrate to MCC 
Used for direct tableting. Need 
more info on the composition, 
properties and how much lactose 
is present with respect to the 
MCC. 
β-lactose 
Sigma Aldrich: Method of 
production not given by supplier. 
> 99% total lactose, < or equal to 
30 %w/w alpha lactose. Chemical 
reagent. 
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2.2 DSC method 
A Q20 DSC apparatus attached to a cooler was used and a nitrogen gas flow of 50mL/min 
was maintained during the experiments. The DSC instrument was calibrated using 99.999% 
pure materials for temperature and enthalpy including indium, tin and lead that have a 
melting points of 156.6°C, 231.9 °C and 327.5 °C respectively (supplied by Perkin Elmer). 
Samples (4±2 mg) of lactose from each test batch were weighed accurately into aluminium 
DSC pans to the nearest 0.001 mg using a Sartorius balance. The pans were sealed with 
lids that had been pre-pierced to allow volatile material to escape during the heating 
procedure. Each sample was equilibrated at 25°C before heating the pan up to 250°C at 
10°C/min. The sample was then set to equilibrate at 250°C, cooling to 25°C at 10°C/min. 
Sample pans were then re-weighed accurately (±0.001 mg) after analysis and the % weight 
loss calculated. 
1.1 2.2 H1 NMR 
Dimethyl sulphoxide (DMSO, 0.7 mL) and 0.05% tetramethyl saline (TMS) (%v/v) (Goss 
Scientific Instruments, Crewe, UK) were used as a solvent and a signal reference for the 
experiment (at 0 ppm) respectively. Samples of β-lactose 4 mg (ACROS Organics, 
Leicestershire) or 6 mg α-lactose monohydrate (Sigma, Dorset) that had been stored at 
room temperature were dissolved in DMSO contained in 400 MHZ Wilmad NMR tubes 
(Sigma, Dorset, UK) under ambient conditions. Lactose samples were allowed to dissolve for 
10 min before starting the analysis using a 400 MHZ Bruker Avance NMR. The length of the 
proton NMR analysis using a QNP probe was ≃10 min and 16 scans were carried out, 
employing a zg30 sequence (30° pulse applied prior to spectrum acquisition).  This 
procedure was employed so that the analysis was carried out within 20 min thereby ensuring 
that minimal anomeric conversion occurred within the aprotic solvent, DMSO (Jawad et al., 
2014; Jawad et al., 2012). However, before this procedure was finalised, the sample 
preparation method was investigated both with respect to the type of environment under 
which the NMR tubes were loaded and the mass of lactose used, as described in Sections 
2.3 and 2.4. 
1.2 2.3 Influence of sample mass  
To investigate the role of sample weight on the precision of the NMR method (where the 
solubility of lactose in DMSO is reported previously to be ≥100 mg/mL (Keith and Walters, 
1991). A predominantly α-lactose powder product (α-lactose monohydrate Sigma; > 96% 
w/w α-anomer) and a predominantly β-lactose powder product (β-lactose, Acros Organics; 
20% w/w α-anomer) were analysed using 2.9 mg/mL, 5.7 mg/mL and 8.6 mg/mL (or 2, 4, 
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and 6 mg in 0.7 mL) DMSO. Samples were analysed within 20 min. The precision of the 
results was determined by comparing the standard deviation (SD) of the area of the 
integrated α-anomer peak with the constant solvent peak area. 
1.3 2.4 H1 NMR sample preparation under nitrogen 
To investigate NMR preparation under nitrogen, NMR tubes containing lactose samples in 
DMSO were prepared inside a nitrogen glove bag (Glas-Col Inflatable glove chamber model 
X) after creating a flow of oxygen free nitrogen gas within the bag (approximately 5 min) and 
sealed with a gas tight seal. The NMR tubes, without caps, were placed in the glove bag with 
the measured DMSO aliquots. A positive pressure was maintained within the bag and after 
sample preparation, solutions of lactose in DMSO were analysed between 1-24 h after 
dissolution to determine the rate of change in the anomeric content of the lactose samples 
that had been prepared using this method. 
2.3 Powder X-ray diffraction (PXRD) 
The crystallinity of the sample was investigated using a PXRD. The Rigaku MiniFlex 600 
diffractometer (Rigaku, Tokyo, Japan) operated with Cu Kα radiation (1.5418 Å) at 40 kV 
and 15 mA, was used to collect patterns in the 2θ range from 3 to 40° at a speed of 2°/min 
and a step size of 0.01°.  
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3 Results 
3.1 DSC analysis of commercially available lactose samples 
A wide range of proprietary lactose samples were analysed. Figure 3 shows a representative 
DSC thermograph combining the results obtained from α-lactose powder (Sigma Aldrich, > 
96 %w/w α lactose) with that obtained from β-lactose powder (ACROS Organics, ≤ 20%w/w 
α lactose). 
  
 
 
 
 
 
 
 
 
Figure 3 DSC analysis of α-lactose and β-lactose samples showing a representative thermogram with 
the integrated peaks for α-lactose monohydrate and β-lactose powder. n=6 for each sample ±SD. 
 
α-lactose contains one hydrate molecule (H2O) per lactose molecule. The water is 
accommodated within the matrix of the lactose crystal structure and is lost at ~ 143°C. As 
shown in Figure 3, the water loss peak integration range is 112.5 –162.5°C with the onset 
occurring at 143.2°C. The sharp nature of the peak indicates that the water is not residual 
content but is indeed the dehydration peak of α-lactose monohydrate (Chen et al., 2015). 
The lactose anomeric peak integration interval was set between 187.5 – 230°C 
(approximately) for α-lactose monohydrate and 212.5–250°C for β-lactose a sigmoidal peak 
integration was used for lactose due to the lowering of the baseline as a consequence of the 
degradation that occurs just after the melting point. The integration intervals were 
determined by considering the differences in the melting point of lactose anomers. This is 
apparent from Figure 3, where the onset of the melting peaks were 215.0°C and 233.5°C for 
α-lactose and β-lactose anomers respectively. The weight losses of α-lactose monohydrate 
and β-lactose powders (mean ± SD) were 5.0 ± 0.4 % w/w and 0.1 ± 0.1 % w/w respectively. 
Sample	name Onset	(°C)	 Enthalpy	(Jg-1) Peak	(°C)	
*Alpha	lactose:	water	
dehydration	 143.2	±0.2 132.2	±4.8 146.9	±0.8 
**Alpha	lactose	melting	peak 215.1	±1.1 119.0	±14.1 219.8	±0.9 
***Beta	lactose	melting	peak 233.4	±0.4 138.6	±6.2 236.4	±0.4 
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A melting reaction and degradation were observed for the α-lactose sample; whereas, only 
one melting peak was observed for the β-lactose sample. 
Indium (the calibration material), being a stable metal produced DSC results that possessed 
greater precision in comparison to those generated by the lactose samples. When indium 
was subjected to DSC (n=6), the coefficient of variation (%CV) was 0.46 for the area of 
enthalpy. The onset temperature demonstrated a %CV of 0.03. The variance in the DSC 
results for the lactose samples were an order of magnitude higher than for the calibration 
material. This difference is reflective of the lower contact area of the lactose particles to the 
DSC pans, as these particles have a high surface area and void volumes within the powder 
bed. 
DSC analysis of lactose reported in the literature has provided varied results. For example, 
the onset of the α-lactose melting peak (°C) has been variously reported as 195°C (Raemy 
and Schweizer, 1983), 215°C (Dudognon et al., 2006), 223°C using a different technique 
(Machado et al., 2000), 210 – 215°C (Kougoulos et al., 2010), 218°C (Kaialy and Nokhodchi, 
2013) and 220°C (Kaialy et al., 2011b).  The melting onset of α-lactose monohydrate in this 
study was 215°C and within the range previously reported. The enthalpy (J g-1) of α-lactose 
monohydrate samples has been reported as 680 (Raemy and Schweizer, 1983), 134 
(Drapier-Beche et al., 1999), 143 (Kaialy et al., 2011a) and 144 (Kaialy et al., 2011b). The 
value obtained in this study was lower (119 ±14 Jg-1). The difference in these values can be 
attributed to the precise method of analysis, where the selection of the integration peak can 
be subjective. The melting temperature is a more precise measurement than the enthalpy 
when the study incorporates an indium standard. Repeatability (inter-day variation) of the 
melting temperature and enthalpy was 0.1% and 2.4% respectively (Toscani et al., 2012). 
The variation in the melting onset and the enthalpies of the α-lactose melting and water loss of the 
lactose samples that were determined by DSC are detailed in  
 
Table 3; the samples were analyzed as shown in Figure 3 DSC analysis of α-lactose and β-
lactose samples showing a representative thermogram with the integrated peaks for α-
lactose monohydrate and β-lactose powder. 
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Table 3 Monohydrate dehydration and α-lactose anomer melting enthalpy with respect to loading 
mass (n=6) obtained by integrating for water loss from 112.5–150°C and integrating the curve for α-
lactose at 186.5– 205°C. 
Sample	name	
α-lactose	
melting	
enthalpy	(Jg-1)	
%CV	
Water	
dehydration	
enthalpy	(Jg-1)	
%CV	 Melting	onset	°C	 %CV	
α−Lactose 
Monohydrate 
119.0 14.3 132.2 3.9 214.8 0.4	
Foremost 312 156.3 11.1 134.1 4.9 215.4 0.4	
Tablettose 80 65.5 5.9 81.0 3.5 211.8 0.5	
Prismalac 91.3 2.6 114.8 2.3 214.6 0.3	
Tablettose 70 144.4 4.3 140.2 2.2 214.6 0.7	
Tablettose 100 132.9 23.9 134.7 3.9 214.8 0.8	
Ludipress 145.2 0.7 152.8 2.5 214.9 1.1	
Granulac 140 142.0 2.1 139.9 2.4 214.1 0.2	
Granulac 230 124.7 11.5 148.4 2.2 215.6 0.1	
Sorbolac 400 122.7 6.8 149.4 5.4 214.0 0.2	
Starlac 95.3 2.4 91.7 5.3 209.6 1.3	
Granulac 70 119.3 5.0 125.0 4.9 211.8 0.2	
Flowlac 90 119.2 5.8 141.6 5.5 212.1 0.1	
Combilac 77.7 9.5 70.1 5.8 215.9 0.3	
Flowlac 100 104.6 6.5 139.0 3.8 215.3 0.4	
Cellactose 65.5 1.5 81.0 2.4 213.7 0.1	
Foremost 316 165.1 1.7 143.5 0.8 213.6 0.0	
MCC 25 98.2 8.1 68.0 2.9 209.8 0.5	
β-lactose N/A N/A N/A N/A 233.4* 0.2	
 
DSC is easy to use and is one of several techniques employed in the analysis of lactose (Table 1).  
The α-lactose in the samples is in the monohydrate form. It was expected that the melting enthalpy of 
the α-lactose would be directly proportional to the water loss enthalpy as the water of hydration is 
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removed from the α-lactose crystal. However, the results did not follow the expected trend (Table 3). It 
appears that there were other variables affecting the correlation between the melting peak and the 
water loss enthalpy. Such factors might include, the method of manufacture and/or the presence of 
other excipients in the lactose. For example, when the enthalpy change was expressed in Joules per 
gram of lactose (as opposed to Joules per gram of the sample loaded ( 
 
Table 3) there was still no statistical correlation between the α-lactose melting enthalpy and 
the water dehydration enthalpy. 
3.2 NMR analysis of lactose 
A sample of β-lactose powder (Sigma, Dorset, 80% β-lactose, 20% w/w α-lactose) was 
analyzed to confirm that the NMR analysis of lactose method was appropriate for 
differentiating between the two anomeric forms of lactose. The peaks corresponding to the 
protons of the α- and β-anomer of lactose occur in the 6–7 ppm region of the NMR spectrum 
(see Figure 4).  
Figure 4 A representative NMR spectrum for a β-lactose powder sample with a magnified region 
showing the position of the α- and β-protons using a 400 MHz NMR. 
Due to the difference in orientation of a carbon in the anomeric forms of lactose, the peak of 
the proton from β-lactose occurs further downfield than the α-lactose and the ratio between 
the two peaks corresponds to the ratio of anomers in the sample. 
α proton 
β proton 
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3.3 Preparation of NMR samples under nitrogen gas 
The analysis of lactose prepared under nitrogen was carried out to ensure that there was no 
significant change in the anomeric content of lactose when using this method of preparation ( 
Figure 5).  
 
Figure 5 Comparison between the change in anomeric content of lactose analyzed up to 24-h with 
and without preparation under nitrogen (6 NMR samples were used for each group to create the data 
points for the trendline). 
 
The change in the anomeric content in the sample stored for 24 h was 4 times faster when 
not stored in nitrogen. If nitrogen was used the α-anomer content decreased from 98.2% to 
97.8% w/w after 24 h, whereas in the absence of the gas the α-anomer content decreased 
from 98.0% to 96.3% w/w. The differences in the changes between 0 to 8 h were not 
statistically significant (t-test; p>0.05). Approximately 30 min after the solution was prepared, 
all the particles were dissolved and a true solution was formed. In the case of nitrogen-
prepared samples, no significant change in the α- and β-ratios were detected over this initial 
30 min preparation time. As can be seen in figure 4, the anomeric content remained constant 
from the first point up to 8 h. 
3.4 Influence of loading mass on the precision of the NMR assay 
Compared to many modern analytical techniques, solution based H1 NMR has relatively 
poor sensitivity. NMR signal to noise ratio is influenced by many factors, but as the intensity 
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of the NMR peaks are, in part, proportional to the amount of analyte present within the 
magnetic field, the more concentrated the solution the better. For small molecules similar to 
the relative molecular mass of lactose, loading masses of 1 to 10 mg dissolved within the 
typical 0.7 mL of an NMR tube are common. However homogenous solutions are required, 
so it is important to avoid precipitation, as this dramatically increases the signal to noise 
ratio. 
NMR has been used successfully to quantify the purity of organic samples when using a 
known internal standard as a reference whereas the DSC can be complicated by the 
complexity of the results (i.e. broad peak, irregular shaped peaks) and the material (i.e. 
particle-pan contact, head space and powder distribution) so that a concentration cannot be 
calculated (Mahajan and Singh, 2013). Quantitative NMR previously demonstrated high 
accuracy (99.9%) and precision (0.35% SD) when creating a calibration graph (Crouch and 
Russell, 2011). Such an application of NMR for the analysis of lactose samples has been 
shown to be precise with standard deviations in the 0.1% range (Jawad et al., 2012).  
The H1 NMR spectra can be affected by the amount of the lactose added to the 0.7mL of 
DMSO required for the experiment. The solubility of both lactose in DMSO is ≥100 mg/mL, 
which means that the lactose sample should fully dissolve in 0.7 mL; however, the time it 
takes to dissolve may vary as encountered during the experiment (Keith and Walters, 1991). 
The undissolved lactose decreases the sensitivity of the assay, which was determined by 
measuring the intensity of sample peak with reference to the solvent peak. If too much 
lactose is added in the DMSO the lactose takes longer to completely dissolve. This can 
cause the NMR run to take longer, due to greater background ‘noise’ cause by the few 
remaining undissolved particles. The results may also become inadequate if there is too 
much sample because the undissolved lactose generates a non-homogeneous of the 
sample and this in turn decreases the sensitivity of the instrument. Samples of lactose 
prepared using nitrogen gas are not affected since the samples were allowed to completely 
dissolve before running the experiment. Thus, sample mass optimisation was determined 
without the use of a nitrogen environment to investigate further the use of less-controlled 
assay conditions. Sample sizes of 2, 4 and 6 mg of α-lactose monohydrate were employed 
(Figure 6  and the amount of undissolved α-lactose particles increased as a function of 
increasing weight but decreased as a function of time. A sample of β-lactose was also 
analyzed similarly and the results are shown in Figure 7 . 
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Figure 6 Sample loading weight for NMR analysis of α-lactose (MEGGLE Granulac 240) samples 
(n=3). The ratio of the α-lactose peak intensity with reference to the solvent (DMSO) peak of 
predominantly α-lactose powder is shown. * α-lactose content ± standard deviation. Error bars = SD. 
The anomeric content for the 2, 4 and 6 mg sample sizes was determined to be 97.1% ±0.7, 
96.7% ±0.075, and 96.9% ±0.08 w/w α-lactose respectively. The results of the analysis of 
the 4 mg samples displayed the lowest standard deviation and the largest peak area 
Figure 6 ). Therefore, 4 mg in 0.7 mL of DMSO was chosen to be the recommended 
optimum concentration when analyzing content lactose samples with high α-anomer content. 
Figure 7 Sample loading weight for NMR analysis of β-lactose (ACROS ORGANICS) samples (n=6). 
The ratio of the α-lactose peak intensity with reference to the solvent (DMSO) peak of predominantly 
β-lactose powder is shown. * α-lactose content ± standard deviation. Error bars = standard deviation.  
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The anomeric content of the assayed β-lactose powder was calculated as 14.6% ± 0.81, 
14.2% ± 1.44, and 13.5% ± 0.21 w/w α-lactose for the 2, 4 and 6 mg samples respectively. 
Therefore, as the 6 mg samples displayed the lowest standard deviation and the highest 
peak area, samples made using this concentration were considered to provide the highest 
precision. An accurate estimate of α-lactose monohydrate, can be obtained using a lower 
sample size when β-lactose is present as an ‘impurity’ in comparison to the case where β-
lactose is the principal component. For an unknown sample, it is recommended to use 6 mg 
as this would lead to a maximum standard deviation of 0.8% anomeric content. Should a 
sample be suspected to contain high alpha content, an additional run with 4 mg is 
recommended. 
3.5 Library of lactose samples analyzed by NMR 
A library of lactose samples was characterized using the NMR analysis method described 
previously (Table 4). Using the results obtained from the sample weight investigation, the 
sample masses of predominantly α- and β-lactose samples that were employed in the 
studies were 4 and 6 mg respectively. 
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Table 4 Library of the anomeric content of commercially available lactose samples analyzed by H1 
NMR n=6 aThe %CV associated with the β-anomer content was the same as that of the α-anomer 
content. bmicrocrystalline cellulose/lactose mixture. 
Sample % α-anomer %CV % α-anomer (manufacturer) % β-anomer
a 
α-Lactose Monohydrate 98.4 0.14 ≥96 % 1.6 
Foremost 312 98.4 0.07 N/A 1.6 
Tablettose 80 98.1 0.28 N/A 1.9 
Prismalac 97.9 0.11 N/A 2.1 
Tablettose 70 97.8 0.14 N/A 2.2 
Tablettose 100 97.8 0.15 N/A 2.2 
Ludipress 97.8 0.12 N/A 2.2 
Granulac 140 97.7 0.20 N/A 2.3 
Granulac 230 97.4 0.07 N/A 2.6 
Sorbolac 400 96.9 0.14 N/A 3.1 
Starlac 96.9 0.08 N/A 3.1 
Granulac 70 96.9 0.21 N/A 3.1 
Flowlac 90 96.1 0.16 N/A 3.9 
Combilac 95.6 0.06 N/A 4.4 
Flowlac 100 95.0 0.12 N/A 5.0 
Cellactoseb 94.6 2.18 N/A 5.4 
Foremost 316 94.1 0.75 N/A 5.9 
MCC 25 84.6 0.64 N/A 15.4 
β-lactose 16.4 1.27 ~20 83.6 
 
The method of production of the lactose products can be found in Table 2. In summary, 
the milled and sieved samples generally possessed a higher α-lactose content than the co-
processed samples where the α-anomer content relative to β-anomer content was as low as 
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84.6%w/w for MCC 25. The samples that were spray-dried exhibited a wide range of 
anomeric content, with the lowest α-lactose content produced by this method being 94.1% 
w/w (i.e. Foremost 316). Some manufacturers did not state the method of production and 
others seemed to use the term α-lactose monohydrate to suggest that the material was 
100% w/w α-lactose. The sample with the highest %CV (2.18%) was found to be the co-
processed material, Cellactose, which is a mixture of 75:25 % w/w α-lactose monohydrate 
and cellulose. 
3.6 Comparison between DSC and NMR analytical techniques 
The data indicated that the enthalpy of water loss obtained by DSC does not show a 
consistent correlation with the α-lactose content determined by NMR (y = 7.6088x - 613.9 
and R² = 0.0992).  DSC has been used as a quantitative tool for sieved samples of lactose 
(Kaialy et al., 2012), but in this study non-sieved samples were employed. Samples were not 
sieved, since the commercially available lactose samples are sold to users that are 
searching for bespoke material that should not require further preparation. Additionally, 
some of the lactose products that were analyzed in the current study did contain other 
excipients where the derived enthalpies were expressed as J g-1 of material rather than J g-1 
of lactose. When these samples were removed from the data set, still no statistical 
correlation was observed. There was also a poor correlation between the melting peak 
enthalpy and anomeric content of the lactose samples (y = 11.756x - 1024.1; R² = 0.1991). 
The mean %CV was also used to compare the precision of each method. The %CV of the 
data from the samples assayed by NMR (0.53) and DSC (6.88) showed that they are very 
different and NMR is more than ten times more precise. Samples of β-lactose were initially 
included in the analysis, but there were no samples that contained 30% – 85% w/w α-
lactose; therefore, the samples plotted include the predominantly α-lactose powders.  
 
3.7 PXRD of lactose samples 
In order to investigate the differences in the anomeric content of some of the lactose library 
samples, PXRD analysis was carried out on samples of lactose that were prepared using 
different methods by the manufacturers (Table 2). A sample of spray-dried, milled, and spray 
agglomeration were analyzed by PXRD. Additionally, α-lactose monohydrate (crystalline) 
and β-lactose (anhydrous; Sigma) were also analyzed by PXRD (Figure 8). 
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Figure 8 Overlay of PXRD spectra of lactose samples 
 
 
There was a variation in the intensity of the peaks between the samples. However, all the 
samples exhibit profiles with clearly defined ‘sharp’ peaks, indicating that the samples are 
mostly crystalline.  
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4 Discussion 
4.1 Pharmaceutical lactose production 
The manufacturing process used to produce lactose powder determines the anomeric 
content of the marketed excipient (Appendix). There are several major manufacturers of 
lactose worldwide, such as those based in the USA (Kerry; Foremost), Netherlands 
(Borculo), Germany (Meggle) and New Zealand (Fonterra) (Rowe et al., 2006). Lactose 
products that are predominantly crystalline α-lactose monohydrate are prepared using 
different milling and sieving conditions that result in different flowability profiles, particle size 
distributions and bulk densities (Nickerson and Moore, 1974).  
Crystalline α-lactose monohydrate possesses a tomahawk shape whereas β-lactose has a 
needle-like shape and may look irregular if the sample is crushed into smaller particle during 
manufacturing processes. Such anomer specific physical differences are likely to affect the 
anomeric content of the final grade when separating the lactose powder by sieving. During 
the production of crystalline lactose powders, the sugar is affected by many external 
parameters that will influence the anomeric content of the final product. For example, water 
activity, temperature, pH and the time taken for unit processes such as crystallization, drying 
and milling will influence the amount of α-lactose and β-lactose observed (Jawad et al., 
2012; Lefort et al., 2006). 
Spray-dried and amorphous lactose products are also available for direct compression to 
form tablets (Meggle, 2018). For predominately amorphous products, the spray-drying 
method requires the lactose to be in solution before the atomization of the solvent in a hot 
environment (usually 100 – 200°C). The fast nature of heat exposure (a few seconds) does 
not allow lactose to crystallize, as the solvent evaporates leaving the amorphous lactose 
product as the residue to be collected. However, for the spray-dried lactose powders 
featuring in table 2 and investigated in this paper, a suspension of alpha lactose 
monohydrate crystals in a lactose solution was used as the feed solution into the spray-dryer 
rather than solely a solution of lactose. Preparative milling was used to reduce the particle 
size of the suspended particles to allow flow through the drying atomizer. The 
manufacturer’s choice of spray-drying is to achieve optimum compressibility and a targeted 
particle size range, but very little has been published on the anomeric distribution of these 
materials. When atomized the droplets of suspension will contain several of the milled 
crystalline α-lactose monohydrate particles, thus it is expected that the resulting powder will 
be highly crystalline. However, the disperse lactose solution surrounding the particles will 
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undoubtedly form an amorphous layer on the surface of these crystals when the water is 
removed in the drying chamber. As the water quickly evaporates, the suspended particles 
within the droplets are forced together leading to an agglomerated particle, with the 
individual fine crystals held together by the amorphous surface layer. The anomeric 
composition of this amorphous surface ‘glue’ is unknown, but as it formed from an aqueous 
solution some beta amorphous lactose will be present. Upon collection and storage, it would 
appear, from both the PXRD results and the DSC measurements presented here, that 
significant concentrations of amorphous lactose do not persist into the final powder. This is 
either a result of the amorphous layer contributing only a small undetectable fraction or the 
amorphous material re-crystallizing over time.  
Flowlac 100 and Flowlac 90 are prepared by the spray-drying of a fine crystal suspension 
(Meggle, 2018). DSC and PXRD, Table 3 and Figure 8, indicate the highly crystalline nature 
of Flowlac powders. These grades have lower amounts of α-lactose, 95 & 96% w/w 
respectively, compared to samples prepared using other methods, where α-lactose is more 
predominant (Table 4). The residual β-lactose present, as discussed above, will have 
originated from the aqueous lactose solution surrounding the suspended crystalline α-
lactose monohydrate particles in the original feed suspension. 
The Flowlac 100 lactose has been reported to show a small re-crystallization peak as 
determined by DSC, when the samples were sieved prior to assay (Kaialy et al., 2012). In 
this study, the re-crystallization peaks were almost non-existent, indicating the low presence 
of amorphous content in the sample, support also by the PXRD data presented in Figure 8. 
Therefore, it is possible that the smaller particle size fraction of this grade of lactose might 
have an observable amorphicity than the sample as supplied (i.e. no preliminary sieving). 
Should any amorphous regions be located on the surface of the lactose this would have 
implications for potential differences in the adhesion of active pharmaceutical ingredient 
(API) to different sized fractions of lactose when used as carrier in DPIs. Such amorphicity, 
because of the higher surface energy in comparison to crystalline lactose may adhere to 
some of the API more tenaciously, resulting in more of the latter being deposited higher in 
the respiratory tract with the greater-sized lactose.  
Batches of pharmaceutical grade lactose are now tailor-made so as to generate the desired 
properties for use in different applications; such as carrier particles in DPIs, fillers in 
capsules and diluents in tablets. The different grades of lactose are routinely distinguished 
by the manufacturer in terms of particle size (distribution); however, the anomeric content as 
a grading is rarely specified. The results reported here show this can vary and may be a 
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factor that should be reported in future quality specifications. Finally, the lactose products 
can be mixed with the other components of the medicine (i.e. API and other excipients), 
using one of the three main blending methods such as dry mixing followed perhaps by wet 
granulation. The latter involves further exposure to small amounts of solvents and potentially 
a humid atmosphere which might subsequently affect the anomer content further. Other 
pharmaceutical processes such as milling, spheronisation, freeze drying, spray-drying etc. 
will also influence the composition of final product (Jawad et al., 2014; Lefort et al., 2006). 
Accordingly, the original isomer composition of each lactose grades, as determined and 
given in Table 4, is likely to change during processing.  
4.2 Stability of lactose and quality assurance 
The stability of certain lactose products has been brought to question by Altamimi et al. 
2017. Lactose production methods, storage and the utilization in medicines can cause 
changes to the anomeric content of the product that is attributable to physical and 
environmental stress such as milling and spray-drying (Willart et al., 2004) and change in 
humidity. When purchasing lactose samples, the specifications that are provided will include 
limits on water loss-on-drying, particle size distribution and the composition of mixture 
products (lactose and MCC). The properties of the product need to be specified with a high 
level of certainty to be acceptable for use by consumers and manufacturers. To date, the 
anomeric content of the lactose material is generally not well characterized and hence not 
always quoted, although some product specifications do indicate an approximate and 
sometimes a minimum % anomeric content to be present in the sample. 
For example, the aerosol performance from carrier-containing DPIs is highly dependent 
upon lactose composition (Traini et al., 2008). The complex nature of commercially lactose 
grades, being dependent on the methods of isolation or preparation results in some of the 
data previously reported in the scientific literature as being difficult to interpret.  The 
significance of amorphous versus crystalline content (Vromans et al., 1987; Rassu et al. 
2006; Omar et al. 2015) for example maybe placed ahead of anomer composition as being 
the determinant factor in tableting properties, despite the latter content varying dependent 
upon the preparations conditions of the lactose. Nevertheless anomer composition has been 
reported previously to influence the consolidation and compaction of tablets (Bolhuis et al. 
1985; Riepma et al. 1990; Riepma et al.1992; Bolhuis and Zuurman 1995), crushing strength 
(Vromans et al. 1985) and disintegration and dissolution (van Kamp et al. 1986). There are 
well-established links between these pharmacopeia parameters and the performance of a 
tablet upon administration therefore; changes in the anomeric content will alter the efficacy 
of tablets and most likely lactose containing medicines in general. Furthermore, since β-
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lactose is markedly more compactable than α-lactose samples (Ilic et al., 2009), this will 
ultimately affect the friability and hardness of tablets that need to pass specific standards set 
by the manufacturer. Stability tests are also carried out before these tests which involve the 
exposure of samples to temperatures of up to 40°C and 75% RH. Such conditions can 
catalyse changes in anomeric content and result in altered tablet properties (ICH, 2003). 
4.3 Lactose analysis methods 
Traditionally employed lactose analysis techniques do not routinely consider anomeric 
content, such as HPLC and enzymatic quantification assays, which have been used to 
quantify lactose in solutions (i.e. milk). Recent studies have shown that the former methods 
are not as adequate as LC-MS to quantify lactose, which proved to have a higher level of 
repeatability and precision (Trani et al., 2017). DSC has also been used widely to analyze 
lactose and is an easy tool that determines the presence of crystalline lactose. The melting 
curve of the lactose anomers can be defined using the technique (ca. 210+°C), but since the 
material degrades at temperatures soon after this, then it is not sufficiently sensitive to carry 
out accurate anomer quantification (Figure 2).  Therefore, although DSC can be used for 
identification of the presence of an anomer, quantification by analysis of the melting peak is 
not feasible (Ilic et al., 2009). Both predominantly α-lactose and β-lactose powders have 
been investigated extensively by DSC in the literature and other studies investigate some 
grades of lactose (Kaialy et al., 2012); however, none of the previous studies have carried 
out a comprehensive analysis of all grades using DSC.  
An advantage of DSC analysis is that it can determine the amorphous content of a lactose 
sample but its sensitivity to do this is again limited by the fact that it requires at least 20% 
w/w amorphous content for the quantification of crystallinity to be meaningful (GombÁs et al., 
2002). If analysts require a qualitative measurement, DSC may be adequate; however, for a 
full quantitative assessment, NMR can be used as it has demonstrated a real-time 
determination of anomeric content. When analyzing DSC curves, there is a certain 
subjectivity involved in determining the exact onset and end of the peak integration.  In 
addition, the origin of the wide variance in the α lactose melting enthalpy will undoubtedly 
have a contribution from mutarotation occurring in the lactose sample present in the DSC 
pan during the heating cycle. Water vapour liberated by the temperature driven dehydration 
will induce inter-conversion between the α and β-lactose anomers as the vapour passes 
through the powder bed before it leaves the DSC pan. It is well known that β-lactose is more 
stable above 90’C in saturated aqueous solutions of lactose, thus an increase in the amount 
of this anomer is expected because dehydration begins at approximately 140’C. The 
enthalpy contribution of mutarotation will be subsumed into the endothermic peak associated 
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with dehydration, which has a broad temperature range. The extent of any mutarotation and 
thus alteration in the anomer ratio in the heated lactose samples will depend on many 
factors, for example it will depend on the starting anomeric content, amount of monohydrate 
present, particle size, loading mass, headspace and the porosity of the particles. All of these 
parameters varied between each type of lactose tested, and so this was reflected in the 
range of enthalpies for both dehydration and melting given in Table 3. The aim of the work 
reported here was to determine the variability in the anomeric content of commercially 
available lactose powders. It would appear that because of many contributing factors, DSC 
was unable to provide quantitative measurements of the anomeric composition, whereas the 
NMR method was able to. The variance of the data presented in Tables 3 & 4 supports this 
conclusion as the mean %CV of the samples analyzed by DSC is five times greater than the 
mean %CV of the results obtained using the NMR technique. The performance of the NMR 
can be attributed to the unambiguous and separate NMR signals for α- and β-lactose as a 
consequence of the difference in molecular structure. 
‘The lack of a correlation between the size of the DSC melting endotherms and the NMR 
results may have also been due to the presence of amorphous content within the samples 
(Table 3). PXRD was carried out on representative samples to explore this potential 
contributing factor. Although the results showed that there was some variation in the 
crystallinity of the lactose samples, an overlay of the PXRD data showed that the samples 
comprised mostly crystalline material. Accordingly amorphous content is not the main 
contributing factor to the poor correlation between the results obtained from the thermal and 
the NMR methods of analysis. Thus, as the temperature of a sample increases during DSC 
analysis, a change in the properties of the crystalline lactose samples occurs which is mostly 
related to the impact of dehydration and particle properties. Therefore, the melting curves 
would not be directly proportional to the anomeric content found in the unambiguous NMR 
spectra of a lactose sample that has not been heated to the same temperatures as the DSC 
sample. 
 
The results of the PXRD experiment did indicate some degree of variation in the peak 
patterns and thus the crystallinity of the samples. The issue with employing PXRD to 
determine the crystallinity of lactose is that there is always a part of the sample that is not α-
lactose monohydrate that can contribute to the intensity of some peaks. For example, there 
is no clear PXRD intensity peak pattern that represents only one lactose anomer because 
there is always an impurity of the other anomer in the sample. In this study it has been 
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shown that the samples that are declared as being α-lactose monohydrate do indeed contain 
some β-lactose by the NMR method. There may be a contribution from the β-lactose to the 
peak being used as a reference. Such impurities can make it difficult to accurately quantify 
the precise % crystallinity of the sample. These observations further support the use of NMR 
in the unambiguous determination of the anomeric composition of lactose samples.’ 
There may be some potential in employing a hyper DSC method to overcome some of the 
challenges encountered when analyzing lactose powder. For example, a high heating rate 
may allow the users to detect the melting point while not allowing the samples sufficient time 
to degrade (Saunders et al., 2004). Other parameters that can affect the results obtained 
when using this technique include the influence of particle size and conduction of the 
material. Better control of water content and the amorphous/crystalline ratio may improve the 
correlation between DSC data and the samples’ anomeric content, but the benefit of the 
NMR data is that they are unambiguous. This is supported by the fact that the ‘uncontrolled’ 
NMR analysis provided close values to the NMR analysis of samples prepared in a 
‘controlled’ nitrogen environment. 
By analysing a library of samples from the market, it is apparent that there is variability in the 
anomer content of different lactose grades from different suppliers (Table 4). The main 
limitation of the NMR technique described in the literature is the time-sensitivity of the 
method (Altamimi et al., 2017; Jawad et al., 2014; Jawad et al., 2012). By preparing samples 
under nitrogen, it was demonstrated that the NMR analysis method became less constrained 
by time, allowing more freedom when running NMR samples while retaining the integrity of 
the analysis. This novel approach ensured a very accurate representation of the anomeric 
content can be established in a number of samples within one working day. 
4.4 NMR method evaluation 
The NMR analysis method of lactose was proven to be simple and fast with an actual 
analysis time of 6 min. Typically in analytical laboratories, NMR samples are loaded and 
analyzed in a queuing/automated fashion, thus it may sometimes be difficult to restrict 
sample waiting times to <20 min. In an attempt to obviate the 20-min restriction on time 
between preparation in DMSO and complete analysis, an alternative preparation method 
using a nitrogen glove bag connected to oxygen free nitrogen gas was developed. By using 
a glove bag to contain a nitrogen atmosphere, many samples can be prepared with relative 
ease. In samples that are prepared under nitrogen, the particles were completely dissolved 
in solution and this enabled an NMR spectrum to be gained with lower background noise 
than samples that were run quickly without nitrogen. 
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After 24 h, a decrease of approximately 0.5% w/w α-lactose was found when using nitrogen, 
whereas in the absence of a nitrogen environment, a change of 1.7% w/w was detected after 
24 h. These data show that mutarotation does occur at a relatively slow rate and thus 
depending upon the accuracy required, it may be acceptable for users to assay the samples 
without the use of nitrogen in the same day if it is acknowledged that an approximately 2% 
error in anomer content is acceptable.  
4.5 Conclusion and recommendations 
Lactose manufacturers employ several techniques to provide the specifications of lactose 
products detailed in pharmacopoeias (Kellam, 2008). For example, In the US 
Pharmacopoeia, anhydrous lactose products that are labelled with a specific purity of 
anomeric content of lactose must, by definition, test the anomeric content of the samples. In 
this case a GC method is advocated where the prescribed method requires several mixing 
and tube transfer steps to produce a 5 µL aliquot for GC injection. Additionally, in the 
pharmacopoeia, the anomeric content is not required to be assessed for the monohydrate 
form of α-lactose.  According to the handbook of pharmaceutical excipients the ‘isomer’ ratio 
of anhydrous lactose powder is not a mandatory test in the European Pharmacopeia but is 
mandatory in the US and the Japanese Pharmacopoeias (Rowe et al., 2006), although there 
is variation between Pharmacopoeia monographs on how to deal with the anomeric 
specification of lactose (α anhydrous) and if it is a requirement. As for the monohydrate and 
spray-dried forms, there is no requirement to determine the anomeric content in the 
pharmacopoeias. 
The results from this study show that there is a variability in the anomeric content in lactose 
products. For the labelled β-lactose sample, the actual value was 5% w/w different from the 
label claim and for samples that were declared to be α-lactose, up to 6% w/w β-anomer 
could be measured in the sample. Several of the other samples did not provided an 
anomeric content value in their specifications. With the revised technique described in this 
study, we would submit that its application for new lactose-containing products be 
considered since there is an emerging opinion in the literature that the anomeric content of 
lactose could play an important role in a medicine’s pharmaceutical performance. For 
example, a study has shown that the anomeric content was a factor in determining the 
efficiency of carrier properties of lactose when employed in DPIs (Kaialy et al., 2011a). 
We suggest a H1 NMR method for the monitoring and surveying of lactose samples in a 
quick and efficient manner. Preparation in nitrogen should be used when samples are left for 
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longer than 20 min before analysis. In time, with further development such a method could 
form the basis of a sound monograph requirement.  
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